Glenmark Pharmaceuticals has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 patients.
Received the manufacturing and marketing approval from the Drugs Controller General of India (DCGI).
Price at ₹103 per tablet, the prescription-based drug will be available as a 200 mg tablet at an MRP of ₹3,500 for a strip of 34 tablets.
The recommended dose of Favipiravir is 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14. It is a prescription-based medicine.
0 Comments